The answer to your question is "no". Trial results are news that will sustain volume and price appreciation, not the (nearly 2 year) "anticipation" of results. And the prior poster was right in that we've seen this movie here before, many times. So far this one looks no different
I guess that's a matter of interpretation. I don't believe that trial completion is the catalyst here as it is simply the end of an already predefined term. Results would be actionable news. We are all pretty good at turning just about every PR into our own "actionable news". For my own personal investing I would consider what we have received to be nice updates but nothing of recent memory to act on. We all watch this stock pretty closely and i haven't seen anyone cite anything that aligns nicely with the increase in volume and SP. I thought maybe the patent awarding was it, then i thought maybe there was a heavy PR coming but neither of those presented unexpected or groundbreaking information and have been simply formalities at this point.
You could be right and this is build up to study results. Perhaps that's the action here but i would have expected a slower build into the SP if that were the case.
I certainly hope i'm wrong and continued efforts to break $2 may indicate there is more going on here but i'm prepared to be back in the 1.80's in the near term.
Market Data 
Markets 
AI
